Kistler-Tiffany Companies’s Blueprint Medicines BPMC Stock Holding History

Kistler-Tiffany Companies’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$6.32K	Hold	100	–	–	﹤0.01%	744
2023 Q1	$4.5K	Hold	100	–	–	﹤0.01%	693
2022 Q4	$4.38K	Hold	100	–	–	﹤0.01%	694
2022 Q3	$7K	Hold	100	–	–	﹤0.01%	634
2022 Q2	$5K	Hold	100	–	–	﹤0.01%	656
2022 Q1	$6K	Hold	100	–	–	﹤0.01%	657
2021 Q4	$11K	Hold	100	–	–	﹤0.01%	580
2021 Q3	$10K	Hold	100	–	–	﹤0.01%	577
2021 Q2	$9K	Hold	100	–	–	﹤0.01%	570
2021 Q1	$10K	Hold	100	–	–	﹤0.01%	520
2020 Q4	$11K	Hold	100	–	–	﹤0.01%	487
2020 Q3	$9K	Hold	100	–	–	﹤0.01%	484
2020 Q2	$8K	Hold	100	–	–	﹤0.01%	465
2020 Q1	$8K	Hold	100	–	–	﹤0.01%	458
2019 Q4	$8K	Hold	100	–	–	﹤0.01%	465
2019 Q3	$7K	Buy	+100	New	+$8.64K	﹤0.01%	480

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Kistler-Tiffany Companies's BPMC Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Blueprint Medicines (BPMC) position steady in Q2 2023 at 100 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #744.

Kistler-Tiffany Companies first reported a position in BPMC in Q3 2019 and has held it in 16 quarters since. The position peaked at $11K in Q4 2021. 222 funds tracked by Wall St. Rank hold BPMC as of Q2 2023.

Kistler-Tiffany Companies held 100 shares of Blueprint Medicines worth $6.32K as of Q2 2023.
Kistler-Tiffany Companies left its Blueprint Medicines share count unchanged in Q2 2023.
Blueprint Medicines made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #744 holding.
Kistler-Tiffany Companies first reported a position in Blueprint Medicines in Q3 2019 and has held it in 16 quarters since.
Kistler-Tiffany Companies's Blueprint Medicines position peaked at $11K in Q4 2021.
222 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.